BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer Promotion Designed to Drive Adoption of CryoStor® and HypoThermosol® in the Biobanking, Drug Discovery, and Regenerative Medicine Markets
BOTHELL, Wash., Dec. 6, 2011 /PRNewswire/ -- BioLife Solutions Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary biopreservation media products for cells, tissues, and organs, today announced the launch of its new corporate website that includes the following features:
- Built on the Genesis Framework for WordPress, which incorporates state of the art code and smart design architecture optimized for search engine visibility, so prospective customers quickly find the website and its biopreservation resources.
- A free product sample offer (http://biolifesolutions.com/sample/) integrated with automatic lead creation in SalesForce.com, BioLife's cloud based customer relationship management system.
- An integrated blog updated with customer product experiences and application notes authored by members of BioLife's Scientific Advisory Board, customers, and partners in the field of biopreservation.
- An updated investor presentation and corporate data sheet.
Mike Rice, BioLife Chief Executive Officer, commented on the launch of the Company's new website by stating, "Our new site has been designed to increase awareness and adoption of our high-quality cGMP HypoThermosol, CryoStor, and BloodStor® biopreservation media products. Many biopreservation practitioners continue to use non-optimized, home-brew cell storage and freeze media formulations. This integrated free product sample offer should generate future revenue, as nearly all prospects decide to become repeat customers once the superior biopreservation efficacy of our pre-formulated, serum-free, protein-free products is demonstrated during a product comparison."
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
SOURCE BioLife Solutions, Inc.